Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Eisai Sets Up Global Oncology and Neurology Business Units Ahead of Schedule
May 8, 2014
- Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
- Suglat Tops Anterio’s "Mind Share" Ranking in GP Market in March; Xarelto Rises Sharply
May 8, 2014
- FDA Grants Priority Review to XTANDI for Add’l Indication: Astellas
May 8, 2014
- Takara Bio Submits IND Application for PII Study of Anticancer Agent HF10 to US FDA
May 8, 2014
- Drug Information Gained Mostly from Sales Reps, Less from Online Promotion: IMS Survey
May 8, 2014
- Nitto Denko Moving Ahead at Full Speed in Japan, US to Develop Nucleic Acid Drug as a Potential Cure for Cirrhosis
May 7, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
May 7, 2014
- Drug Makers’ Plans for MRs Becoming Clearer; Takeda to Bolster Force, Sanofi Making Big Reduction
May 7, 2014
- Ono, Nissan Chemical End Licensing Deal on Thrombocytopenia Agent
May 2, 2014
- Otsuka Granted European Approval for Multidrug-Resistant TB Medicine
May 2, 2014
- Oncolys Obtains Patent on Manufacturing Process for Anti-HIV Drug OBP-601 in Japan
May 2, 2014
- Nihon Chouzai Pharmaceutical Sales Reach 23,192 Million Yen in FY2013
May 1, 2014
- AZ Files for Domestic Approval of Bydureon Pen Formulation
May 1, 2014
- Chugai’s US Subsidiary Appoints Gianella-Borradori as Its Chief Medical Officer
May 1, 2014
- Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
- Daiichi Sankyo Ceases PIII Study of Nimotuzumab for Lung Cancer in Japan
April 30, 2014
- Takeda to Introduce New Performance-Based Incentive Programs for Board of Directors, Senior Execs
April 30, 2014
- Kissei Taps Morozumi as New President, COO
April 30, 2014
- Chugai Discontinues Multinational PIII of Onartuzumab for Lung Cancer
April 30, 2014
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…